On Monday, Pfizer and BioNTech announced they have asked the FDA to grant an emergency use authorization for their new version of a Covid-19 vaccine that’s been adapted to be specific to the BA.4/BA.5 versions of the Omicron variant.
Category: technology
InnovationRx: WHO Declares Monkeypox Emergency; Plus: Covid’s Animal Origins
InnovationRx is your weekly digest of healthcare news. Sign up!
15 Million Downloaded Pregnancy Trackers That May Give Data To Cops Without A Warrant—Should You Worry?
A Forbes analysis of two pregnancy and ovulation trackers owned by a $3.6 billion media conglomerate show they reserve the right to share data with law enforcement at their discretion. Privacy activists want such companies to do more to protect users i…
Butterfly Network Inks Deal To Provide Portable Ultrasound Devices To Medical University Of South Carolina
The company’s devices will be used in clinical and research settings first before being introduced to the medical school.
Novavax Claims Positive Results From Early Trials Of Combination Covid/Flu Vaccine
The company will be moving into more clinical trials for the vaccine through 2022 and 2023.
Pfizer Signs Deal With UNICEF To Distribute Its Covid Antiviral Drug
The pharmaceutical giant will provide 4 million courses of Paxlovid to 95 low- and middle-income countries.
Covid Year 3 Will Be Better, Experts Agree, Unless Rich Countries Ignore The Pandemic Elsewhere
The worst of the pandemic is behind us, experts told Forbes, in part because the first two years provided valuable tools for the continued fight against both Covid and future disease epidemics.
Pfizer’s Started Clinical Trials For Its Covid Antiviral In Kids
The company’s antiviral pill, Paxlovid, is currently authorized for high-risk patients aged 12 and up. This study will look at kids above age 6.
Moderna Aims To Make Vaccines Against 15 Deadly Diseases—And The Next Pandemic
The company’s new public health initiative aims to work with middle- and low-income countries to combat diseases, while working with scientists worldwide to develop vaccines for the next potentially deadly outbreak.
Novavax Reports Enduring Covid Immune Response Six Months After Vaccination
The company’s protein-based vaccine showed strong efficacy over time, and it reported $1.1 billion in revenue in 2021.
